

# PROVIDER Update



CONTRACTUAL | MAY 24, 2019 | UPDATE 19-388 | 3 PAGES

## Injectable Medication HCPCS/DOFR Crosswalk Reference Table Update – 2nd Quarter 2019

Approved updates are effective June 30, 2019

On April 16, 2019, the Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates are effective June 30, 2019, and listed on pages 2 and 3. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net\* and CalViva Health *Provider Participation Agreement (PPA)*.

The update includes:

- DOFR categories for eight new injectable medications (that can be billed using 10 HCPCS codes).
- HCPCS code changed for one injectable medication.
- Addition of secondary category for 10 existing injectable medications.

### ADDITIONAL INFORMATION

Relevant sections of the provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library, located on the provider website at [provider.healthnet.com](http://provider.healthnet.com).

Providers are encouraged to access the provider portal online at [provider.healthnet.com](http://provider.healthnet.com) for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact CalViva Health at 1-888-893-1569.

**THIS UPDATE APPLIES TO  
MEDI-CAL PROVIDERS:**

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

### PROVIDER SERVICES

1-888-893-1569  
[www.healthnet.com](http://www.healthnet.com)

## ADDITIONS TO INJECTABLE MEDICATION HCPCS/DOFR CROSSWALK

The following medications have been approved by the P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from Health Net and CalViva Health participating physician groups (PPGs).

### New Drugs:

HCPCS	Drug Name	Generic Name	Primary Category	Secondary Category
J3590	Cablivi®	Caplacizumab-yhdp	Self-injectable	
J3490	Clorotekal®	Chloroprocaine hydrochloride injection, for intrathecal use	Therapeutic inj	
J9999	Elzonris™	Tagraxofusp-erzs injection, for intravenous use	Therapeutic inj	Chemotherapy
90739	Hepelisav-b®	Hepatitis B vaccine (recombinant), adjuvanted] solution for intramuscular injection	Therapeutic inj	Immunizations
J3590	Nuzyra™	Omadacycline for injection	Therapeutic inj	
C9399, J3590	Revcovi™	Elapegademase-lvlr injection, for intramuscular use	Therapeutic inj	
J3590	Ultomiris™	Ravulizumab-cwvz injection, for intravenous use	Therapeutic inj	
J3490	Xerava™	Eravacycline dihydrochloride injection, for intravenous use	Therapeutic inj	

## UPDATES/CHANGES TO INJECTABLE MEDICATION PROCEDURE CODES OR MEDICATIONS

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

### Updates:

HCPCS	Drug Name	Generic Name	Comment
J7329	Trivisc™	Sodium hyaluronate	Changed from J3490

## CATEGORY CHANGES TO HCPCS CROSSWALK

Secondary category additions were made to the HCPCS crosswalk for the following existing injectable medications.

### Category Changes:

HCPCS	Drug Name	Generic Name	Primary Category	Secondary Category
J0714	Avycaz®	Ceftazidime-avibactam Injection	Therapeutic inj	Home health/infusion**
J1743	Elaprase®	Idursulfase, 1 mg	Therapeutic inj	Home health/infusion**
J3380	Entyvio™	Vedolizumab for injection, for intravenous use	Therapeutic inj	Home health/infusion**

---

**CATEGORY CHANGES TO HCPCS CROSSWALK, continued**

HCPCS	Drug Name	Generic Name	Primary Category	Secondary Category
Q5109	Ixifi™	Infliximab-qbtx, biosimilar, 10 mg	Therapeutic inj	Home health/infusion**
J2480	Kanuma™	Sebelipase alfa injection, for intravenous use	Therapeutic inj	Home health/infusion**
C9399, J9999	Poteligeo®	Mogamulizumab-kpkc injection, for intravenous use	Therapeutic inj	Chemotherapy*
J3358	Stelara® iv	Ustekinumab, for intravenous injection, 1 mg	Therapeutic inj	Home health/infusion**
J2185	Vabomere™	Meropenem-vaborbactam for IV soln	Therapeutic inj	Home health/infusion**
J1322	Vimizim®	Elosulfase alfa	Therapeutic inj	Home health/infusion**
C9399, J3490	Zemdri™	Plazomicin injection, for intravenous use	Therapeutic inj	Home health/infusion**

\*HCPCS codes were taken from the Centers for Medicare & Medicaid Services (CMS) HCPCS website at [www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html](http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html).

\*\*When administered by a nurse in a home setting.